{"pmid":32375025,"title":"Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.","text":["Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.","Coronaviruses make use of a large envelope protein called spike (S) to engage host cell receptors and catalyze membrane fusion. Because of the vital role that these S proteins play, they represent a vulnerable target for the development of therapeutics. Here, we describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. Crystal structures of these VHHs bound to their respective viral targets reveal two distinct epitopes, but both VHHs interfere with receptor binding. We also show cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. These data provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronavirus outbreaks.","Cell","Wrapp, Daniel","De Vlieger, Dorien","Corbett, Kizzmekia S","Torres, Gretel M","Wang, Nianshuang","Van Breedam, Wander","Roose, Kenny","van Schie, Loes","Hoffmann, Markus","Pohlmann, Stefan","Graham, Barney S","Callewaert, Nico","Schepens, Bert","Saelens, Xavier","McLellan, Jason S","32375025"],"abstract":["Coronaviruses make use of a large envelope protein called spike (S) to engage host cell receptors and catalyze membrane fusion. Because of the vital role that these S proteins play, they represent a vulnerable target for the development of therapeutics. Here, we describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. Crystal structures of these VHHs bound to their respective viral targets reveal two distinct epitopes, but both VHHs interfere with receptor binding. We also show cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. These data provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronavirus outbreaks."],"journal":"Cell","authors":["Wrapp, Daniel","De Vlieger, Dorien","Corbett, Kizzmekia S","Torres, Gretel M","Wang, Nianshuang","Van Breedam, Wander","Roose, Kenny","van Schie, Loes","Hoffmann, Markus","Pohlmann, Stefan","Graham, Barney S","Callewaert, Nico","Schepens, Bert","Saelens, Xavier","McLellan, Jason S"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32375025","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cell.2020.04.031","keywords":["covid-19","mers","sars","sars-cov-2","nanobody"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496443613185,"score":9.490897,"similar":[{"pmid":32332765,"title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.","text":["Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2). In this report, we generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study. The fusion proteins are then characterized. Both fusion proteins have a high binding affinity for the receptor-binding domains of SARS-CoV and SARS-CoV-2 and exhibit desirable pharmacological properties in mice. Moreover, the fusion proteins neutralize virus pseudotyped with SARS-CoV or SARS-CoV-2 spike proteins in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they have potential applications in the diagnosis, prophylaxis, and treatment of SARS-CoV-2.","Nat Commun","Lei, Changhai","Qian, Kewen","Li, Tian","Zhang, Sheng","Fu, Wenyan","Ding, Min","Hu, Shi","32332765"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2). In this report, we generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study. The fusion proteins are then characterized. Both fusion proteins have a high binding affinity for the receptor-binding domains of SARS-CoV and SARS-CoV-2 and exhibit desirable pharmacological properties in mice. Moreover, the fusion proteins neutralize virus pseudotyped with SARS-CoV or SARS-CoV-2 spike proteins in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they have potential applications in the diagnosis, prophylaxis, and treatment of SARS-CoV-2."],"journal":"Nat Commun","authors":["Lei, Changhai","Qian, Kewen","Li, Tian","Zhang, Sheng","Fu, Wenyan","Ding, Min","Hu, Shi"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332765","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1038/s41467-020-16048-4","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493968973826,"score":404.0571},{"pmid":32413276,"title":"Identification of Human Single-Domain Antibodies against SARS-CoV-2.","text":["Identification of Human Single-Domain Antibodies against SARS-CoV-2.","The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike protein, containing the receptor-binding domain (RBD) and S1 subunit involved in receptor engagement, is a potential therapeutic target. We describe the development of a phage-displayed single-domain antibody library by grafting naive complementarity-determining regions (CDRs) into framework regions of a human germline immunoglobulin heavy chain variable region (IGHV) allele. Panning this library against SARS-CoV-2 RBD and S1 subunit identified fully human single-domain antibodies targeting five distinct epitopes on SARS-CoV-2 RBD with subnanomolar to low nanomolar affinities. Some of these antibodies neutralize SARS-CoV-2 by targeting a cryptic epitope located in the spike trimeric interface. Collectively, this work presents a versatile platform for rapid antibody isolation and identifies promising therapeutic anti-SARS-CoV-2 antibodies as well as the diverse immogneic profile of the spike protein.","Cell Host Microbe","Wu, Yanling","Li, Cheng","Xia, Shuai","Tian, Xiaolong","Kong, Yu","Wang, Zhi","Gu, Chenjian","Zhang, Rong","Tu, Chao","Xie, Youhua","Yang, Zhenlin","Lu, Lu","Jiang, Shibo","Ying, Tianlei","32413276"],"abstract":["The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike protein, containing the receptor-binding domain (RBD) and S1 subunit involved in receptor engagement, is a potential therapeutic target. We describe the development of a phage-displayed single-domain antibody library by grafting naive complementarity-determining regions (CDRs) into framework regions of a human germline immunoglobulin heavy chain variable region (IGHV) allele. Panning this library against SARS-CoV-2 RBD and S1 subunit identified fully human single-domain antibodies targeting five distinct epitopes on SARS-CoV-2 RBD with subnanomolar to low nanomolar affinities. Some of these antibodies neutralize SARS-CoV-2 by targeting a cryptic epitope located in the spike trimeric interface. Collectively, this work presents a versatile platform for rapid antibody isolation and identifies promising therapeutic anti-SARS-CoV-2 antibodies as well as the diverse immogneic profile of the spike protein."],"journal":"Cell Host Microbe","authors":["Wu, Yanling","Li, Cheng","Xia, Shuai","Tian, Xiaolong","Kong, Yu","Wang, Zhi","Gu, Chenjian","Zhang, Rong","Tu, Chao","Xie, Youhua","Yang, Zhenlin","Lu, Lu","Jiang, Shibo","Ying, Tianlei"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413276","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.chom.2020.04.023","keywords":["cr3022","rbd","sars-cov-2","nanobody","single-domain antibody","trimeric interface"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319092551681,"score":380.7807},{"pmid":32454513,"title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection.","text":["Human neutralizing antibodies elicited by SARS-CoV-2 infection.","The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions(1-3). SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor(2,4-6). Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions.","Nature","Ju, Bin","Zhang, Qi","Ge, Jiwan","Wang, Ruoke","Sun, Jing","Ge, Xiangyang","Yu, Jiazhen","Shan, Sisi","Zhou, Bing","Song, Shuo","Tang, Xian","Yu, Jinfang","Lan, Jun","Yuan, Jing","Wang, Haiyan","Zhao, Juanjuan","Zhang, Shuye","Wang, Youchun","Shi, Xuanling","Liu, Lei","Zhao, Jincun","Wang, Xinquan","Zhang, Zheng","Zhang, Linqi","32454513"],"abstract":["The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions(1-3). SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor(2,4-6). Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions."],"journal":"Nature","authors":["Ju, Bin","Zhang, Qi","Ge, Jiwan","Wang, Ruoke","Sun, Jing","Ge, Xiangyang","Yu, Jiazhen","Shan, Sisi","Zhou, Bing","Song, Shuo","Tang, Xian","Yu, Jinfang","Lan, Jun","Yuan, Jing","Wang, Haiyan","Zhao, Juanjuan","Zhang, Shuye","Wang, Youchun","Shi, Xuanling","Liu, Lei","Zhao, Jincun","Wang, Xinquan","Zhang, Zheng","Zhang, Linqi"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454513","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41586-020-2380-z","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667881798493798400,"score":360.85406},{"pmid":32384820,"title":"Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.","text":["Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.","SARS-CoV-2 enters cells using its Spike protein, which is also the main target of neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated viral infection are important for studying immunity. Because SARS-CoV-2 is a biosafety-level-3 virus, one way to simplify such assays is to pseudotype biosafety-level-2 viral particles with Spike. Such pseudotyping has now been described for single-cycle lentiviral, retroviral, and vesicular stomatitis virus (VSV) particles, but the reagents and protocols are not widely available. Here, we detailed how to effectively pseudotype lentiviral particles with SARS-CoV-2 Spike and infect 293T cells engineered to express the SARS-CoV-2 receptor, ACE2. We also made all the key experimental reagents available in the BEI Resources repository of ATCC and the NIH. Furthermore, we demonstrated how these pseudotyped lentiviral particles could be used to measure the neutralizing activity of human sera or plasma against SARS-CoV-2 in convenient luciferase-based assays, thereby providing a valuable complement to ELISA-based methods that measure antibody binding rather than neutralization.","Viruses","Crawford, Katharine H D","Eguia, Rachel","Dingens, Adam S","Loes, Andrea N","Malone, Keara D","Wolf, Caitlin R","Chu, Helen Y","Tortorici, M Alejandra","Veesler, David","Murphy, Michael","Pettie, Deleah","King, Neil P","Balazs, Alejandro B","Bloom, Jesse D","32384820"],"abstract":["SARS-CoV-2 enters cells using its Spike protein, which is also the main target of neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated viral infection are important for studying immunity. Because SARS-CoV-2 is a biosafety-level-3 virus, one way to simplify such assays is to pseudotype biosafety-level-2 viral particles with Spike. Such pseudotyping has now been described for single-cycle lentiviral, retroviral, and vesicular stomatitis virus (VSV) particles, but the reagents and protocols are not widely available. Here, we detailed how to effectively pseudotype lentiviral particles with SARS-CoV-2 Spike and infect 293T cells engineered to express the SARS-CoV-2 receptor, ACE2. We also made all the key experimental reagents available in the BEI Resources repository of ATCC and the NIH. Furthermore, we demonstrated how these pseudotyped lentiviral particles could be used to measure the neutralizing activity of human sera or plasma against SARS-CoV-2 in convenient luciferase-based assays, thereby providing a valuable complement to ELISA-based methods that measure antibody binding rather than neutralization."],"journal":"Viruses","authors":["Crawford, Katharine H D","Eguia, Rachel","Dingens, Adam S","Loes, Andrea N","Malone, Keara D","Wolf, Caitlin R","Chu, Helen Y","Tortorici, M Alejandra","Veesler, David","Murphy, Michael","Pettie, Deleah","King, Neil P","Balazs, Alejandro B","Bloom, Jesse D"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32384820","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.3390/v12050513","keywords":["293t-ace2","ace2","alayt","covid-19","sars-cov-2","spike","coronavirus","cytoplasmic tail","lentiviral pseudotype","luciferase","neutralization assay"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666340102085804034,"score":356.14694},{"pmid":32425270,"pmcid":"PMC7231725","title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.","text":["Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.","The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here we report the rapid identification of SARS-CoV-2 neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. From 8,558 antigen-binding IgG1(+) clonotypes, 14 potent neutralizing antibodies were identified with the most potent one, BD-368-2, exhibiting an IC50 of 1.2 ng/mL and 15 ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. BD-368-2 also displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected hACE2-transgenic mice. Additionally, the 3.8A Cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the antibody's epitope overlaps with the ACE2 binding site. Moreover, we demonstrated that SARS-CoV-2 neutralizing antibodies could be directly selected based on similarities of their predicted CDR3H structures to those of SARS-CoV neutralizing antibodies. Altogether, we showed that human neutralizing antibodies could be efficiently discovered by high-throughput single B-cell sequencing in response to pandemic infectious diseases.","Cell","Cao, Yunlong","Su, Bin","Guo, Xianghua","Sun, Wenjie","Deng, Yongqiang","Bao, Linlin","Zhu, Qinyu","Zhang, Xu","Zheng, Yinghui","Geng, Chenyang","Chai, Xiaoran","He, Runsheng","Li, Xiaofeng","Lv, Qi","Zhu, Hua","Deng, Wei","Xu, Yanfeng","Wang, Yanjun","Qiao, Luxin","Tan, Yafang","Song, Liyang","Wang, Guopeng","Du, Xiaoxia","Gao, Ning","Liu, Jiangning","Xiao, Junyu","Su, Xiao-Dong","Du, Zongmin","Feng, Yingmei","Qin, Chuan","Qin, Chengfeng","Jin, Ronghua","Xie, X Sunney","32425270"],"abstract":["The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here we report the rapid identification of SARS-CoV-2 neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. From 8,558 antigen-binding IgG1(+) clonotypes, 14 potent neutralizing antibodies were identified with the most potent one, BD-368-2, exhibiting an IC50 of 1.2 ng/mL and 15 ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. BD-368-2 also displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected hACE2-transgenic mice. Additionally, the 3.8A Cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the antibody's epitope overlaps with the ACE2 binding site. Moreover, we demonstrated that SARS-CoV-2 neutralizing antibodies could be directly selected based on similarities of their predicted CDR3H structures to those of SARS-CoV neutralizing antibodies. Altogether, we showed that human neutralizing antibodies could be efficiently discovered by high-throughput single B-cell sequencing in response to pandemic infectious diseases."],"journal":"Cell","authors":["Cao, Yunlong","Su, Bin","Guo, Xianghua","Sun, Wenjie","Deng, Yongqiang","Bao, Linlin","Zhu, Qinyu","Zhang, Xu","Zheng, Yinghui","Geng, Chenyang","Chai, Xiaoran","He, Runsheng","Li, Xiaofeng","Lv, Qi","Zhu, Hua","Deng, Wei","Xu, Yanfeng","Wang, Yanjun","Qiao, Luxin","Tan, Yafang","Song, Liyang","Wang, Guopeng","Du, Xiaoxia","Gao, Ning","Liu, Jiangning","Xiao, Junyu","Su, Xiao-Dong","Du, Zongmin","Feng, Yingmei","Qin, Chuan","Qin, Chengfeng","Jin, Ronghua","Xie, X Sunney"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425270","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cell.2020.05.025","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837804933122,"score":354.7599}]}